These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30520245)

  • 1. PCSK9 inhibitors and diabetes: Translational biology to clinical practice.
    Chilton RJ; Oliveros R; Gallegos KM; Pham S
    Diabetes Obes Metab; 2019 Mar; 21(3):451-453. PubMed ID: 30520245
    [No Abstract]   [Full Text] [Related]  

  • 2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
    Ortega Martínez de Victoria E
    Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
    [No Abstract]   [Full Text] [Related]  

  • 3. Do PCSK9 inhibitors reduce cardiovascular events?
    Kolber MR; Nickonchuk T; Turgeon R
    Can Fam Physician; 2018 Sep; 64(9):669. PubMed ID: 30209099
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?
    Preiss D; Baigent C
    Nat Rev Nephrol; 2017 Aug; 13(8):450-451. PubMed ID: 28669994
    [No Abstract]   [Full Text] [Related]  

  • 5. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
    Karalis DG; Mallya UG; Ghannam AF; Elassal J; Gupta R; Boklage SH
    Am J Cardiol; 2018 May; 121(10):1155-1161. PubMed ID: 29548678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 7. The year in cardiology 2015: prevention.
    Chapman MJ; Blankenberg S; Landmesser U
    Eur Heart J; 2016 Feb; 37(6):510-9. PubMed ID: 26726043
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors.
    Scherer DJ; Nelson AJ; Psaltis PJ; Nicholls SJ
    Intern Med J; 2017 Aug; 47(8):856-865. PubMed ID: 28401639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 inhibitors: clinical evidence and implementation.
    Sabatine MS
    Nat Rev Cardiol; 2019 Mar; 16(3):155-165. PubMed ID: 30420622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia.
    Patel RS; Scopelliti EM; Olugbile O
    Ann Pharmacother; 2018 Oct; 52(10):1000-1018. PubMed ID: 29667842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
    Kazi DS; Penko J; Coxson PG; Moran AE; Ollendorf DA; Tice JA; Bibbins-Domingo K
    JAMA; 2017 Aug; 318(8):748-750. PubMed ID: 28829863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors.
    Ioannidis JPA
    JAMA; 2017 Aug; 318(5):419-420. PubMed ID: 28738115
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia.
    Ascaso JF
    Endocrinol Nutr; 2016; 63(6):255-7. PubMed ID: 27050861
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
    Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
    J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target.
    Sabatine MS; Giugliano RP
    JAMA Cardiol; 2017 Sep; 2(9):935-936. PubMed ID: 28768310
    [No Abstract]   [Full Text] [Related]  

  • 18. New Drugs for Lowering LDL-Cholesterol.
    Bădescu C; Rezuş E; Bădescu L; Dima N; Rezuş C
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):485-90. PubMed ID: 30044561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes.
    Hess CN; Low Wang CC; Hiatt WR
    Annu Rev Med; 2018 Jan; 69():133-145. PubMed ID: 29095667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol.
    Whayne TF
    Drugs; 2018 Mar; 78(3):287-291. PubMed ID: 29396831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.